March 17, 2016
Knoxville, TN, UNITED STATES, May 17, 2016– ABT Molecular Imaging has successfully installed and implemented the BG-75 Biomarker Generator System for on-site 18F-FDG production at Aga Khan University Hospital in Karachi, Pakistan.
In concert with ABT’s distribution partner in the region, Allmed Solutions, the BG-75 System was installed in December 2015, placed into clinical operation in January 2016, and has produced over 400 clinical 18F-FDG doses to date.
“Aga Khan is the top medical University in Pakistan, and we are very proud to partner with such a prestigious institution, which is the only JCIA accredited tertiary healthcare facility in the country”, said Peter Kingma, President and CEO of ABT Molecular Imaging.
Dr. Maseeh uz Zaman, Nuclear Medicine Chief at Aga Khan, stated: “I have believed for some time that global expansion of PET would depend, to a significant extent, on moving from existing centralized models for 18F-FDG production, to decentralized models, utilizing a compact, user-friendly cyclotron with automated radiochemistry and quality control.” “ABT has delivered on this promise with the Biomarker Generator, enabling us to produce cost effective and reliable on-demand 18F-FDG in-house.”
About ABT Molecular Imaging, Inc: ABT Molecular Imaging is a medical imaging company marketing the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use. The company was founded in 2006 by industry experts in the molecular imaging industry. ABT’s investor partners include Intersouth Partners, River Cities Capital and two TNInvestco Funds, Council & Enhanced Tennessee Fund and Limestone Fund.
For all media enquires please contact:
Rick Rippin, Director of Sales
Telephone: +1 407-615-0776 / Email: email@example.com
The Company is headquartered in Knoxville, Tennessee. For more information visit www.abt-mi.com